News
NANOBIOTIX Provides Updates on Clinical Development Continuity in the Context of the COVID-19 Crisis
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’) today announced updates to the Company’s operational and global development plan in light of the
VFMCRP and Cara Therapeutics announce positive results from global KALM-2 pivotal phase-III trial of KORSUVA™ injection in haemodialysis patients with Pruritus
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200420005949/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
VALBIOTIS publishes its annual results for 2019
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200420005808/en/
Valbiotis pipeline (Photo: Business Wire)
VALBIOTI
Aurinia Appoints Industry Veteran Timothy P. Walbert to its Board of Directors
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
Biofrontera: Geschäfte laufen schleppend – das soll nun helfen!
Das März-Quartal von Biofrontera (WKN: 604611) war laut am Freitag verkündeter vorläufiger Zahlen wenig überraschend durch die COVID-19-Pandemie bestimmt.
Die negativen Einfüsse spürte der deutsche
Sangamo Appoints D. Mark McClung as Executive Vice President and Chief Business Officer
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of D. Mark McClung as Executive Vice President and Chief Business Officer. Mr. McClung will
VALBIOTIS beschleunigt seine klinische Pipeline-Entwicklung im Hinblick auf neue Indikationen: Reduzierung von kardiovaskulären und Lebersteatose-Risiken
VALBIOTIS (Paris: ALVAL) (FR0013254851 – ALVAL / PEA/-KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Prävention und Bekämpfung von
Evotec: Neue Knaller-Kooperation
Evotec (WKN: 566480) verkündet heute eine strategische Partnerschaft und Beteiligungsvereinbarung mit leon-nanodrugs aus München. Mit der auf Innovation ausgerichteten Zusammenarbeit will Evotec
Charles River Laboratories Schedules First-Quarter 2020 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2020 financial results on Thursday, May 7th, before the market opens. A conference call has been scheduled to
VALBIOTIS Accelerates Its Pipeline Clinical Development in New Indications: Cardiovascular and Hepatic Steatosis Risk Reduction
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200415005751/en/
An advanced pipeline of active substances (Graphic
QIAGEN Launches Therascreen BRAF Test as Companion Diagnostic to a BRAFTOVI® (encorafenib) Based Regimen in Metastatic Colorectal Cancer
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced launch of its novel therascreen® BRAF V600E RGQ PCR Kit (therascreen BRAF V600E Kit) following U.S. Food and Drug
Clovis Oncology Announces Debt Exchange Transaction
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that on April 14, 2020 it entered into a privately negotiated exchange agreement with a holder of its 2.50% Convertible Senior Notes due 2021
Epigenomics: Das wird für Rückenwind sorgen!
Epigenomics (WKN: A11QW5) habe „umfassende Maßnahmen zur Kostensenkung“ in allen Unternehmensbereichen eingeleitet, wie es heute mitteilt. Ziel ist die Sicherung von Liquidität in Zeiten von Corona.
QIAGEN Announces Preliminary Q1 2020 Results
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary sales and adjusted earnings per share results for the first quarter of 2020.
Net sales rose approximately 9% at
QIAGEN gibt vorläufige Ergebnisse des ersten Quartals 2020 bekannt
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gibt die vorläufigen Umsatzergebnisse und den vorläufigen bereinigten Gewinn je Aktie für das erste Quartal 2020 bekannt.
Der bereinigte
Sangamo Announces Closing of Biogen Collaboration Agreement
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the closing of its previously announced sale of stock to Biogen Inc. (Nasdaq: BIIB) and that the global
Pfizer Advances Battle Against COVID-19 on Multiple Fronts
Pfizer Inc. (NYSE: PFE) today announced important advances in the battle against the global COVID-19 pandemic.
As outlined in Pfizer’s five-point plan, the company has been collaborating across
Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), and Pfizer Inc. (NYSE: PFE) today disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine
U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) for the treatment
Pfizer to Hold Virtual-Only 2020 Annual Meeting of Shareholders
Pfizer Inc. (NYSE: PFE) today announced that its 2020 Annual Meeting of Shareholders will be held in a virtual-only format due to continued public health concerns related to coronavirus / COVID-19
Pfizer and The Pfizer Foundation Donate $40 Million in Charitable Grants, Expand Product Access and Mobilize Colleagues to Combat COVID-19 Pandemic
Pfizer Inc. (NYSE: PFE) and The Pfizer Foundation today announced the commitment of $40 million in medical and charitable cash grants to help combat the global health effects of the COVID-19
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 2, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
ICON Signs New Service Agreement With Pfizer
ICON plc, (NASDAQ: ICLR) a leading global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced
Novocure Provides Business Update Related to COVID-19
Novocure (NASDAQ: NVCR) today provided an update on its response to the global COVID-19 pandemic and an initial evaluation of the impact the pandemic may have on Novocure’s general business